In recent years there has been a growing interest for exploring and describing the attitude of patients towards treatments provided by professionals working in mental health services. Not only the interest has been focused on whether patients perceive drug treatments as beneficial or harmful, but also on what patients think about non-phar-macological interventions, including psychological thera-pies and rehabilitative intervention programs provided by day-care centres, self-help groups or outpatient facilities. In the present issue of Epidemiologia e Psichiatria Sociale three Editorials discuss the current state of the art on this topic, and highlight the profound implications that the subjective attitude of patients may have in determining the long-term success or failure of comprehensive and articulated treatment plans.

Only recently, success criteria became more ambitious and include a more thorough consideration of negative symptoms and cognitive dysfunction. The most important change within the last decade is the long overdue consideration of the patient's perspective. His/her subjective well-being, often unchanged or even worsened by typical antipsychotics, was neglected for a long time. One reason was the prejudice that schizophrenic patients are not able to self-rate their quality of life. Another reason was the belief that such data are not necessary because the psychiatrists' perspective, “objective” psychopathology, includes these domains. Among other scales, a self-report instrument has been constructed to evaluate “subjective well-being under neuroleptics” (SWN). This scale was used in numerous open and controlled trials, indicating: a) patients, if no longer acutely psychotic or suffering from severe cognitive deficits, are able to reliably assess their subjective well-being, b) high SWN is correlated with high compliance, c) atypical antipsychotics increase SWN, and d) individual improvements of SWN and of PANSS are not strongly related. Moreover, several studies found that early improvement of subjective well-being is a major predictor for the chance of remission. All these data indicate that a better consideration of the patient's perspective is possible and necessary.

The aim of this contribution is to explore how different treatments are experienced from the perspective of individu-als with mental illnesses. We used data drawn from qualitative, narrative interviews. When asked to discuss their lives, people rarely discuss their psychiatric treatment. When asked about treatment, they describe hospitalization and medication but not out-patient care. What is described as most helpful are relationships with others, especially in 24-hour centers, clubhouses, and user-run organizations; places where they report feeling that they are accepted, understood, and cared about. Also important are experiences of “giving back” to others and employment as ways of increasing participants’ sense of self-worth and value. Participants also indicated the importance of med-ication, but described protracted processes of having to find the right prescriber, the right medication, at the right dosage, and taking the medication long enough to derive its benefits. For others, symptoms were described as being an integral part of who they were and not something they wanted to eliminate. Traditional treatments (e.g., medication), if given by a practitioner who understands the person and is willing to try to find the right medication and dosage, may serve as a foundation for instrumental experiences of being accepted, understood, valued, and being able to give back to others.

This contribution initially describes some traditional tools that are commonly used to measure drug tolerability, including measures that take into considerations both clinicians’ and patients’ views. Subsequently, it highlights a few studies that compared the patient and clinician's perspective in the evaluation of drug tolerability, trying to understand whether health care providers and patients perceive antipsychotic tolerability in different ways, and whether these different ways may have implica-tions in terms of treatment adherence and outcome. Finally, some clinical and research implications are suggested and discussed.

In the study of the beneficial and adverse effects of psychotropic drugs, in addition to experimental studies (Barbui et al., 2007), epidemiological studies may provide interesting insights. A key methodological aspect in drug utilization studies is how drug consumption should be measured. Specifically, the need is to end up with a single variable that may be reliably used to indicate the overall consumption, for each patient included in a certain survey, of one specific drug (for example one antipsychotic, say haloperidol) or a specific drug class (for example second-generation antipsychotics) or a group of drugs (for example psychotropic drugs, including antipsychotics plus antidepressants plus benzodiazepines). Not only such a variable has to accommodate the problem that actual doses cannot be directly compared, but also that many patients often receive more than one drug, belonging to different or to the same pharmacological class. A methodology is therefore needed to convert each medication dosage into a standardised measure that allows to calculate, for each patient, a cumulative index of drug consumption. Standardised measures of drug consumption are also beneficial for national and international comparisons, for the evaluation of time trends in drug use, and for assessing the public health impact of specific events (for example a change in reimbursement status).

The continuous performance test (CPT) is a behavioural assessment of attentional modulation of the motor system (Rosvold et al., 1956). It has firstly been used in patients with brain injuries and then applied to assess sustained attention and vigilance in epilepsy, brain tumor, dementia, schizophrenia and other psychiatric diseases, such as attention-deficit hyperactivity disorder (ADHD) and anxiety disorders (Rosvold et al., 1956; Honey et al., 2005; Kanaka et al., 2008). There are several versions of the test. For instance, the X-CPT version presents randomly different stimuli and subjects are asked to push a button only on presentation of the target stimuli (X). In the AX-CPT version, the subjects are required to push the button only when a cue stimulus is presented before the target one (A before X). The following items are measured for the X and AX tasks: omission errors (number of times subjects fail to respond to target stimulation), commission errors (number of times subjects respond to non target stimulation), average reaction time and coefficient of variance for both correct reactions and commission errors (Suwa et al., 2004). There are other versions, such as the CPT-not X version where the subjects are asked not to push a button when the target stimulus (X) is presented; the Degraded Stimuli (DS)-CPT (Nuechterlein, 1983); the CPT playing card version (Rutschmann et al., 1977); and the CPT Identical Pairs version (Cornblatt et al., 1988), which is a more difficult task prepared to assess high risk population. Interestingly, the Identical Pairs version has been included in the Matrics neurocognitive assessment, a consensus cognitive battery for clinical trials of cognition in schizophrenia (Nuechterlein et al., 2008).

Introduction – There is a need to develop composite indicators to monitor mental health care in countries such as Spain, where there is wide variability of care systems in 17 different regions. The aim of this study is to generate and to test the usability of synthetic indexes in Andalusia (Southern Spain). Method – Seven mental health indicators were selected by expert opinion from a previous list of simple indicators used to compare mental health care systems across Spain (Psicost-74). A Geographical Information Systems (GIS) was used to delineate 71 sectors based on the catchment areas of the mental health centers in Andalusia. Synthetic indexes were obtained through linear combinations of simple indicators via Principal Components Analysis (PCA), using activity data from the Mental Health Information System of Andalusia (SISMA). Maps of these indexes were drawn for 71 catchment areas. Results – Two synthetic indexes were obtained and showed high consistency in the PCA. The Care Load Index (component 1) related to population size and total outpatient care provided within the area. The Case Load Index (component 2) related to assisted morbidity in relation to the population size. The care load index was higher in populated urban areas, whereas the case load was higher in rural areas. Discussion – Care and case load indexes show a different pattern in urban and rural areas. This may be related to a different underlying model of care related to the degree of urbanisation. Geographical Information Systems (GIS) improved recognition and assessment of the spatial phenomena related to the mental health care system, and support policy decision making process in mental health.

Declaration of Interest: None.

Aims – Genetics can offer new resources to epidemiology. This review will consider recent findings regarding the link between stress and depression as an example to illustrate the added value of employing genetics in epidemiological studies. Methods – Systematic review of medical and psychological databases. Results – Genetic and environmental factors may correlate. This suggests the potential for genetic mediation of the exposure to the environment. Gene-environment correlations can help epidemiologists to better understand causal pathways and suggest effective therapeutic strategies. Genetic and environmental factors may also interact. This suggests the potential for genetic modification of environmental effects on disease risk. Gene-environment interactions can help epidemiologists to identify vulnerable individuals and strata-specific environmental effects. Conclusions – New models of disease based on the interplay between genes and environments are providing epidemiology with a new set of testable hypotheses that will advance our understanding of mental health and illness.

Declaration of Interest: Dr. Danese is holder of the Wellcome Trust Research Training Fellowship in Clinical Science.

Background – The purpose of this article is to review the procedures to establish measurement validity in crosscultural comparative research, including recent developments in the quantitative assessment of cross-cultural construct validity. Methods – A narrative review, illustrated by selected examples, of methods in four areas – formative conceptual research, translation and adaptation, criterion validity and construct validity. Results – Valid assessment across cultures requires qualitative research to investigate the cultural relevance of the construct, a careful translation and adaptation of a common measure, followed by pre-testing and cognitive interviews on the populations to be tested. Full criterion validation across diverse cultures may be a chimera given the difficulty in establishing a universally applicable ‘gold standard'. Quantitative analyses can, however, have a part to play in establishing construct validity across cultures. Scale internal consistency, inter-item and item-total correlations and test-retest reliability provide basic support for the viability of a measure in a new cultural setting. Exploratory factor analysis can be used to compare factors and factor loadings. The hypothesis of ‘measurement invariance’ across countries and cultures can be tested explicitly using confirmatory factor analysis (common underlying factors and factor loadings) and Rasch models (common hierarchality of items). Despite measurement invariance, threshold effects arising from cultural differences in norms, or expectations, or expressions of mental distress may still be a problem. Conclusions – There are few examples in the cross-cultural mental health literature of demonstrably valid culture-fair comparison. Much more, could, in principle, be done either to demonstrate measurement invariance, or to identify and explore sources of heterogeneity.

Declaration of Interest: None.

Aims The aim of this paper is to summarise the effects of cannabis use on appetite and energy balance, and to subsequently investigate the possible implications this may have in patients with psychosis, in whom a high prevalence of cannabis use has been reported. Methods – A narrative review based on the recent literature regarding cannabis use in the gen-eral population and patients with psychosis. Results – The short-term abilities of cannabis to increase appetite and body weight, through actions on the endogenous endocannabinoid system, have been well characterised throughout the literature. The long term effects of cannabis use are however unclear and only a minority of studies have been conducted in the general population with overall conflicting results. In terms of the effects of cannabis in patients with psychosis, there has only been one study to date that has investigated this and interestingly found cannabis use to be associated with increased body weight and blood glucose levels, thus providing evidence that cannabis use may be an important contributing factor to the reduced life expectancy, as is currently observed in this vulnerable patient group. Conclusions – It is clear from the literature that patients with psychosis are at a high risk of metabolic and cardiovascular disease in comparison to the general population. However the contribution of cannabis use to this risk is as of yet undetermined and further long term studies are need to confirm current findings and evaluate hypothesised mechanisms.

Declaration of Interest: None.

Aims – Psychosis is a traumatic experience for both sufferers and their families. The morbidity and mortality associated with psychosis may be improved by an assertive, specialised, multidisciplinary approach to care, provided at the earliest opportunity. Early Intervention in Psychosis (EIP) uses such approach to improve the individual's short and long-term symptomatic and functional outcome, as well as quality of life. However, there is still controversy about whether this type of intervention is effective enough to justify its associated costs. Methods – We reviewed evidence from the literature on EIP for schizophrenia spectrum and non-affective psychoses, with particular attention to evidence on its effectiveness in reducing the duration of untreated symptoms, preventing relapses and reducing admission rates, reducing suicide rates, and reducing treatment costs. Results – There is preliminary evidence that EIP may be effective in delaying transition to psychosis, reducing DUP, preventing relapses, reducing admission and suicidal rates, and reducing treatment costs. Discussion – EIP remains a stimulating multidisciplinary approach to psychosis and a demanding commitment for mental health professionals and service developers.

Declaration of Interest: None.

Aims – To date only a few studies investigated the clinical reasons supporting and explaining non-classical antipsychotic prescriptions. The present study was carried out to develop concepts which help understand this phenomenon in a natural setting, giving emphasis to views of clinicians according to quali – quantitative research methodologies. Subjects – From the South-Verona Psychiatric Case Register all antipsychotic prescriptions issued during 2005 were extracted. Concurrent prescribing of two or more antipsychotics, prescribing antipsychotic drugs outside the licensed indications, and outside the licensed ranges of doses reported in the Italian National Formulary, were considered non-classical prescriptions. Reasons for non-classical prescriptions were collected by means of brainstorming sessions with clinicians. Non-classical prescriptions and the corresponding reasons were grouped according to whether they were “clinically sound” or “clinically not sound”. Results – During 2005 a total of 259 patients received 376 non-classical prescriptions. The most frequently reported reasons for non-classical prescribing were that prescriptions were inherited from another clinician with or without benefit, and that prescriptions were motivated by the need of reducing psychotic symptoms. More than 60% of these non-classical prescriptions were categorised as “clinically sound”. Clinically not sound prescriptions were related with negative clinicians’ views and opinions about the patient/clinician relationship. Conclusion – Clinically not sound prescriptions appeared just a reflection of a problematic doctor/patient relationship, where no individual treatment plan existed and psychiatric visits had the only goal of monitoring ongoing prescriptions.

Declaration of Interest: This study received no funding. We have no conflicts of interest.

Negli ultimi anni il modello categoriale della psicosi e della schizofrenia in particolare, è stato riconsiderato a favore di una visione dimensionale. Questa assume che I sintomi psicotici differiscono in modo quantitativo dalle normali esperienze psichiche distribuendosi lungo un continuum che va dalla popolazione clinica affetta da schizofrenia ad individui con disturbo di personalità, fino alla popolazione generale che può mostrare esperienze simil psicotiche (Hanssen et al., 2003; Johns & Phil, 2005). Tale continuità fenomenologica è suggerita da studi che mostrano che le dimensioni del fenotipo della psicosi subclinica sono molto simili a quelle identificate nei disturbi clinici (Van Os et al. 2000; Van Os & Tamminga, 2007; Rossler et al., 2007). Sono state infatti riportate dimensioni positive e negative sia in ambito clinico che subclinico, mentre più incerta appare la presenza della dimensione disorganizzazione (Vollema & Hoijtink, 2000; van Os et al., 2002). Vari studi hanno riportato che i fenotipi clinico e non clinico condividono fattori di rischio, meccanismi psicologici ed i pattern epidemiologici (Sharpley & Peters,1999; Johns & van Os, 2001; van Os et al., 2001), fornendo un'ulteriore prova che l'espressione clinica e subclinica delle psicosi fanno parte dello stesso continuum.